No Data
China Approves Baiyunshan Pharma Unit's Supplementary Application for Traditional Chinese Drug
Baiyunshan (600332.SH): The subsidiary has received approval for the supplementary pharmaceutical application.
On November 21, Gelonghui reported that baiyunshan ph (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. (referred to as "Zhongyi Pharmaceutical"), received the "Notification of Approval for Supplementary Application of Pharmaceutical" issued by the National Medical Products Administration. Zhongyi Pharmaceutical submitted this pharmaceutical supplementary application to the National Medical Products Administration on October 22, 2024, and it was accepted on October 25, 2024. The compound cold remedy capsule is used for the symptoms of wind-heat cold, including fever, slight aversion to cold, body aches, dry mouth and thirst, nasal congestion with thick mucus, red and swollen throat, cough, and yellow thick phlegm. This pharmaceutical was originally produced by the company's subsidiary Guangzhou Baiyunshan Qixing.
The baiyunshan ph (600332.SH) subsidiary He J Gong Pharmaceutical Factory has obtained approval for the new production line and production scope.
baiyunshan ph (600332.SH) issued a notice that the company's subsidiary Guangzhou baiyunshan ph Pharmaceutical Group Co., Ltd. baiyun...
Baiyunshan (00874.HK) has had a shareholding reduction of 0.664 million shares by Norges Bank.
On November 20, Gelonghui reported that according to the latest equity disclosure information from the Stock Exchange, on November 14, 2024, baiyunshan ph (00874.HK) was reduced by Norges Bank in the market by 664,000 shares at an average price of 18.312 Hong Kong dollars per share, involving about 12.1592 million Hong Kong dollars. After the shareholding reduction, the latest number of shares held by Norges Bank is 14.935 million shares, and the shareholding ratio has decreased from 7.09% to 6.79%.
Guangzhou Baiyunshan Pharmaceutical Unit Gets Additions to Drug Production License
With declining performance and senior executives falling from power, why can't baiyunshan (00874) rise up relying on domestic "Viagra"?
Whether it is the early involvement in the "network removal" incident, where certain pharmaceutical products in provinces like shanxi, anhui, guizhou, shandong were stripped of their online procurement qualifications; or the failure of its subsidiary Guangzhou Pharmaceuticals' IPO, or the turmoil in senior management and decline in performance since 2024, all indicate that baiyunshan ph's development may not be smooth.
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed DownNo Data
No Data
